Immuneering Corp (IMRX): Price and Financial Metrics

Immuneering Corp (IMRX): $1.51

0.18 (-10.65%)

POWR Rating

Component Grades








Add IMRX to Watchlist
Sign Up

Industry: Biotech




#338 of 351

in industry

IMRX Price/Volume Stats

Current price $1.51 52-week high $11.92
Prev. close $1.69 52-week low $1.30
Day low $1.48 Volume 242,900
Day high $1.67 Avg. volume 474,306
50-day MA $1.61 Dividend yield N/A
200-day MA $5.15 Market Cap 44.78M

IMRX Stock Price Chart Interactive Chart >

Immuneering Corp (IMRX) Company Bio

Immuneering Corporation provides genetic, genomic, and proteomic data analysis services for pharmaceutical companies to generate biological insights that enhance the clinical and commercial success of medicines. The company was incorporated in 2008 and is based in Cambridge, Massachusetts.

IMRX Latest News Stream

Event/Time News Detail
Loading, please wait...

IMRX Latest Social Stream

Loading social stream, please wait...

View Full IMRX Social Stream

Latest IMRX News From Around the Web

Below are the latest news stories about IMMUNEERING CORP that investors may wish to consider to help them evaluate IMRX as an investment opportunity.

Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

- Dosing of first patient in the Phase 1/2a clinical trial expected in early 2024 - CAMBRIDGE, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop universal-RAS/RAF medicines for broad populations of cancer patients, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for IMM-6-415, paving the way for the company to initiate a Phase 1/2a clinic

Yahoo | December 12, 2023

Here's Why We're Watching Immuneering's (NASDAQ:IMRX) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | November 29, 2023

Immuneering to Present at the 35th Annual Piper Sandler Healthcare Conference

CAMBRIDGE, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that management will present at the 35th Annual Piper Sandler Healthcare Conference to discuss the company’s pipeline, platform, and business strategy. Participating will be Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer

Yahoo | November 20, 2023

Immuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates

-Dose evaluation portion of IMM-1-104 Phase 1/2a trial approximately two-thirds enrolled; Immuneering’s recommendation for a Phase 2 dose expected in early 2024 - - Expanded clinical development plan for IMM-1-104, Phase 2a portion of study now includes 5 arms (3 monotherapy, 2 combination) and additional sites and investigators - - First IMM-1-104 Phase 2a patient expected to be dosed in early 2024, with initial data from multiple arms expected in 2024 – - IND for IMM-6-415 on track for filing

Yahoo | November 9, 2023

Immuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference

– Expanded benchmarking of IMM-1-104 as a single agent across more than 190 patient-aligned models in humanized 3D-tumor growth assays demonstrated high sensitivity in a wide range of MAPK-driven tumor types, including models of RAS and RAF mutant melanoma, pancreatic cancer, and lung cancer – IMM-1-104 in combination with gemcitabine or paclitaxel drove enhanced anti-tumor activity in humanized 3D-tumor growth assays across multiple pancreatic cancer models – Strength of preclinical activity da

Yahoo | October 12, 2023

Read More 'IMRX' Stories Here

IMRX Price Returns

1-mo 2.72%
3-mo -41.02%
6-mo -80.59%
1-year -86.53%
3-year N/A
5-year N/A
YTD -79.46%
2023 51.55%
2022 -70.01%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!